European Neuropsychopharmacology
Volume 20, Issue 6 , Pages 369-378 , June 2010

Effects of chronic nicotine on food intake and anxiety-like behaviour in CB1 knockout mice

  • S.Andreea Bura

      Affiliations

    • These authors contributed equally to this work.
    • ,
  • Aurelijus Burokas

      Affiliations

    • These authors contributed equally to this work.
    • ,
  • Elena Martín-García

      Affiliations

    • These authors contributed equally to this work.
    • ,
  • Rafael Maldonado

      Affiliations

    • Corresponding Author InformationCorresponding author. Laboratori de Neurofarmacologia, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, PRBB Barcelona, Spain, Dr. Aiguader 88, 08003 Barcelona, Spain. Tel.: +34 933160824; fax: +34 933160901.

Received 18 November 2009 ,Revised 18 January 2010 ,Accepted 3 February 2010.

References 

  1. Andersson K, Arner P. Systemic nicotine stimulates human adipose tissue lipolysis through local cholinergic and catecholaminergic receptors. Int. J. Obes. Relat. Metab. Disord. 2001;25:1225–1232
  2. Aso E, Renoir T, Mengod G, Ledent C, Hamon M, Maldonado R, et al. Lack of CB1 receptor activity impairs serotonergic negative feedback. J. Neurochem. 2009;109:935–944
  3. Balerio GN, Aso E, Berrendero F, Murtra P, Maldonado R. Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur. J. NeuroSci. 2004;20:2737–2748
  4. Balerio GN, Aso E, Maldonado R. Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology (Berl). 2006;184:504–513
  5. Barbano MF, Castane A, Martin-Garcia E, Maldonado R. Delta-9-tetrahydrocannabinol enhances food reinforcement in a mouse operant conflict test. Psychopharmacology (Berl). 2009;205:475–487
  6. Bellocchio L, Cervino C, Pasquali R, Pagotto U. The endocannabinoid system and energy metabolism. J. Neuroendocrinol. 2008;20:850–857
  7. Belzung C, Le Pape G. Comparison of different behavioral test situations used in psychopharmacology for measurement of anxiety. Physiol. Behav. 1994;56:623–628
  8. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le FG, Oury-Donat F, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 2003;63:908–914
  9. Bernaards CM, Twisk JW, Snel J, van MW, Kemper HC. In a prospective study in young people, associations between changes in smoking behavior and risk factors for cardiovascular disease were complex. J. Clin. Epidemiol. 2005;58:1165–1171
  10. Berrendero F, Mendizabal V, Robledo P, Galeote L, Bilkei-Gorzo A, Zimmer A, et al. Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. J. Neurosci. 2005;25:1103–1112
  11. Bullen C. Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease. Expert. Rev. Cardiovasc. Ther. 2008;6:883–895
  12. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J. Neurosci. 2004;24:2708–2715
  13. Castañé A, Berrendero F, Maldonado R. The role of the cannabinoid system in nicotine addiction. Pharmacol. Biochem. Behav. 2005;81:381–386
  14. Castañé A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology. 2002;43:857–867
  15. Chen H, Hansen MJ, Jones JE, Vlahos R, Bozinovski S, Anderson GP, et al. Regulation of hypothalamic NPY by diet and smoking. Peptides. 2007;28:384–389
  16. Cohen C, Kodas E, Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol. Biochem. Behav. 2005;81:387–395
  17. Cook JW, Spring B, McChargue D. Influence of nicotine on positive affect in anhedonic smokers. Psychopharmacology (Berl). 2007;192:87–95
  18. Cota D. The role of the endocannabinoid system in the regulation of hypothalamic–pituitary–adrenal axis activity. J. Neuroendocrinol. 2008;20(Suppl 1):35–38
  19. Damaj MI, Kao W, Martin BR. Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J. Pharmacol. Exp. Ther. 2003;307:526–534
  20. Di Marzo V, Bifulco M, De PL. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 2004;3:771–784
  21. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 2005;8:585–589
  22. Forget B, Hamon M, Thiebot MH. Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology (Berl). 2005;181:722–734
  23. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del AI, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J. Neurosci. 2002;22:9612–9617
  24. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob. Res. 2007;9:315–327
  25. Inui A. Feeding and body-weight regulation by hypothalamic neuropeptides-mediation of the actions of leptin. Trends Neurosci. 1999;22:62–67
  26. Kirkham TC. Endocannabinoids in the regulation of appetite and body weight. Behav. Pharmacol. 2005;16:297–313
  27. Lamota L, Bermudez-Silva FJ, Marco EM, Llorente R, Gallego A, Rodriguez de FF, et al. Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats. Neuropharmacology. 2008;54:194–205
  28. Liu RH, Mizuta M, Matsukura S. Long-term oral nicotine administration reduces insulin resistance in obese rats. Eur. J. Pharmacol. 2003;458:227–234
  29. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int. J. Obes. (Lond). 2005;29:183–187
  30. Mabley JG, Pacher P, Southan GJ, Salzman AL, Szabo C. Nicotine reduces the incidence of type I diabetes in mice. J. Pharmacol. Exp. Ther. 2002;300:876–881
  31. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006;29:225–232
  32. Mano-Otagiri A, Iwasaki-Sekino A, Ohata H, Arai K, Shibasaki T. Nicotine suppresses energy storage through activation of sympathetic outflow to brown adipose tissue via corticotropin-releasing factor type 1 receptor. Neurosci. Lett. 2009;455:26–29
  33. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl). 2002;159:379–387
  34. Matias I, Gonthier MP, Orlando P, Martiadis V, De PL, Cervino C, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 2006;91:3171–3180
  35. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 2005;115:1298–1305
  36. Perkins KA. Effects of tobacco smoking on caloric intake. Br. J. Addict. 1992;87:193–205
  37. Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes. Metab. 2005;7:65–72
  38. Pomerleau OF, Pomerleau CS. Behavioural studies in humans: anxiety, stress and smoking. Ciba Found. Symp. 1990;152:225–235
  39. Ravinet TC, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003;284:R345–R353
  40. Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 2004;28:640–648
  41. Rodriguez de FF, Fernandez-Ruiz JJ, Murphy L, Eldridge JC, Steger RW, Bartke A. Effects of delta-9-tetrahydrocannabinol exposure on adrenal medullary function: evidence of an acute effect and development of tolerance in chronic treatments. Pharmacol. Biochem. Behav. 1991;40:593–598
  42. Spring B, Cook JW, Appelhans B, Maloney A, Richmond M, Vaughn J, et al. Nicotine effects on affective response in depression-prone smokers. Psychopharmacology (Berl). 2008;196:461–471
  43. Thornton-Jones ZD, Vickers SP, Clifton PG. The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food. Psychopharmacology (Berl). 2005;179:452–460
  44. Tizabi Y, Overstreet DH, Rezvani AH, Louis VA, Clark E, Janowsky DS, et al. Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology (Berl). 1999;142:193–199
  45. Viveros MP, Marco EM, File SE. Nicotine and cannabinoids: parallels, contrasts and interactions. Neurosci. Biobehav. Rev. 2006;30:1161–1181
  46. Ward SJ, Dykstra LA. The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav. Pharmacol. 2005;16:381–388
  47. Weidenfeld J, Bodoff M, Saphier D, Brenner T. Further studies on the stimulatory action of nicotine on adrenocortical function in the rat. Neuroendocrinology. 1989;50:132–138
  48. Winders SE, Grunberg NE. Effects of nicotine on body weight, food consumption and body composition in male rats. Life Sci. 1990;46:1523–1530
  49. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 1999;96:5780–5785

PII: S0924-977X(10)00022-2

doi: 10.1016/j.euroneuro.2010.02.003

European Neuropsychopharmacology
Volume 20, Issue 6 , Pages 369-378 , June 2010

Article Tools

* Image Usage & Resolution